This report categorizes one unit of a percutaneous nephrostomy set as all the necessary devices required to gain access in order to establish a nephrostomy tract and place a nephrostomy tube or ureteral stent. The choice of access system depends on which guidance method (ultrasonography, conventional fluoroscopy or CT) is employed. In general, a percutaneous nephrostomy set includes one or two puncture needles, guidewires, introducing catheters, cannulas and dilators. Nephrostomy balloon catheters are used to establish nephrostomy tracts and can come in kits which include the dilation system, balloons, port grips, sheath locks, inflation ports and sheaths. The market for nephrostomy devices includes percutaneous nephrostomy sets, nephrostomy balloon catheters, and nephrostomy drainage tubes. Although devices can be purchased as part of sets/kits, they are also sold individually.
Table of Contents
TABLE OF CONTENTS
LIST OF FIGURES
LIST OF CHARTS
EXECUTIVE SUMMARY
EUROPEAN UROLOGICAL DEVICE MARKET OVERVIEW
COMPETITIVE ANALYSIS
MARKET TRENDS
MARKET DEVELOPMENTS
MARKETS INCLUDED
PROCEDURES INCLUDED
KEY REPORT UPDATES
VERSION HISTORY
RESEARCH METHODOLOGY
- 1.1. RESEARCH SCOPE
- 1.2. IDATA'S 9-STEP METHODOLOGY
- Step 1: Project Initiation & Team Selection
- Step 2: Prepare Data Systems and Perform Secondary Research
- Step 3: Preparation for Interviews & Questionnaire Design
- Step 4: Performing Primary Research
- Step 5: Research Analysis: Establishing Baseline Estimates
- Step 6: Market Forecast and Analysis
- Step 7: Identify Strategic Opportunities
- Step 8: Final Review and Market Release
- Step 9: Customer Feedback and Market Monitoring
DISEASE OVERVIEW
- 2.1. BASIC ANATOMY
- 2.1.1. Human Urinary System
- 2.2. URINARY PATHOLOGY AND DISORDERS
- 2.2.1. Benign Prostate Hyperplasia (BPH)
- 2.2.2. Urinary Incontinence
- 2.2.3. Urinary Tract Infections (UTI)
- 2.2.4. Kidney Stones
- 2.2.5. Bladder Prolapse
- 2.2.6. Overactive Bladder
- 2.2.7. Prostatitis
- 2.2.8. Erectile Dysfunction (ED)
- 2.2.9. Cancer
- 2.2.9.1.1. Prostate Cancer
- 2.2.9.1.2. Bladder Cancer
- 2.3. PATIENT DEMOGRAPHICS
- 2.3.1. Benign Prostatic Hyperplasia
- 2.3.2. Urinary Incontinence
- 2.3.3. UTI
- 2.3.4. Kidney Stones
- 2.3.5. Erectile Dysfunction
- 2.3.6. Overactive Bladder
- 2.3.7. Prostatitis
- 2.3.8. Cancer
- 2.3.8.1. Prostate Cancer
- 2.3.8.2. Bladder Cancer
PRODUCT ASSESSMENT
- 3.1. PRODUCT PORTFOLIOS
- 3.2. CLINICAL TRIALS
- 3.2.1. Boston Scientific
- 3.2.2. C.R. Bard
- 3.2.3. Coloplast
- 3.2.4. Dornier MedTech
- 3.2.5. Ethicon
- 3.2.6. GE (Oncura)
- 3.2.7. Hollister
- 3.2.8. Lumenis
- 3.2.9. Olympus
- 3.2.10. Teleflex
- 3.2.11. WellSpect Healthcare
COUNTRY PROFILES
- 4.1. INTRODUCTION
- 4.1.1.1. Population
- 4.1.1.2. Median Age
- 4.1.1.3. GDP Per Capita
- 4.1.1.4. Price Index
- 4.2. GERMANY
- 4.3. FRANCE
- 4.4. UNITED KINGDOM
- 4.5. ITALY
- 4.6. SPAIN
- 4.7. BENELUX
- 4.8. SCANDINAVIA
- 4.9. AUSTRIA
- 4.10. SWITZERLAND
- 4.11. PORTUGAL
NEPHROSTOMY DEVICE MARKET
- 5.1. INTRODUCTION
- 5.2. MARKET OVERVIEW
- 5.3. MARKET ANALYSIS AND FORECAST
- 5.3.1. Total Nephrostomy Device Market
- 5.3.2. Percutaneous Nephrostomy Access Market
- 5.3.3. Balloon Dilator Market
- 5.3.4. Nephrostomy Tube Market
- 5.4. DRIVERS AND LIMITERS
- 5.4.1. Market Drivers
- 5.4.2. Market Limiters
- 5.5. COMPETITIVE MARKET SHARE ANALYSIS
ABBREVIATIONS
APPENDIX II: COMPANY PRESS RELEASES